EQUILLIUM, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
EQUILLIUM, INC. (EQ) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.09 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- EQUILLIUM, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.09M, a 93.25% increase year-over-year.
- EQUILLIUM, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $930.00K, a 49.76% increase year-over-year.
- EQUILLIUM, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $401.00K, a 60.10% decline year-over-year.
- EQUILLIUM, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $563.00K, a 40.86% decline year-over-year.
- EQUILLIUM, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $2.32M, a 38.08% decline from fiscal 2024.
- EQUILLIUM, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $3.75M, a 6.18% decline from fiscal 2023.
- EQUILLIUM, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $4.00M, a 17.43% decline from fiscal 2022.
- EQUILLIUM, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $4.84M, a 9.77% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $1.09M 10-Q · filed 2026-08-13 | $2.02M derived: sum of 2 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $930.00K 10-Q · filed 2026-08-13 | ||||
| 2025-12-31 | $2.32M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | $401.00K 10-Q · filed 2025-11-13 | $964.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.58M derived: sum of 3 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $563.00K 10-Q · filed 2026-08-13 | $1.18M derived: sum of 2 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $621.00K 10-Q · filed 2026-08-13 | ||||
| 2024-12-31 | $3.75M 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | $1.00M 10-Q · filed 2025-11-13 | $1.96M derived: sum of 2 quarters · filed 2025-11-13 | $2.93M derived: sum of 3 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $952.00K 10-Q · filed 2025-11-13 | $1.92M derived: sum of 2 quarters · filed 2025-11-13 | |||
| 2024-03-31 | $972.00K 10-Q · filed 2025-11-13 | ||||
| 2023-12-31 | $4.00M 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | $979.00K 10-Q · filed 2024-11-13 | $1.91M derived: sum of 2 quarters · filed 2024-11-13 | $2.95M derived: sum of 3 quarters · filed 2024-11-13 | ||
| 2023-06-30 | $934.00K 10-Q · filed 2024-11-13 | $1.97M derived: sum of 2 quarters · filed 2024-11-13 | |||
| 2023-03-31 | $1.04M 10-Q · filed 2024-11-13 | ||||
| 2022-12-31 | $4.84M 10-K · filed 2024-03-25 | ||||
| 2022-09-30 | $1.19M 10-Q · filed 2023-11-08 | $2.49M derived: sum of 2 quarters · filed 2023-11-08 | $3.79M derived: sum of 3 quarters · filed 2023-11-08 | ||
| 2022-06-30 | $1.30M 10-Q · filed 2023-11-08 | $2.60M derived: sum of 2 quarters · filed 2023-11-08 | |||
| 2022-03-31 | $1.30M 10-Q · filed 2023-11-08 | ||||
| 2021-12-31 | $4.41M 10-K · filed 2023-03-23 | ||||
| 2021-09-30 | $1.15M 10-Q · filed 2022-11-14 | $2.21M derived: sum of 2 quarters · filed 2022-11-14 | $3.26M derived: sum of 3 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $1.06M 10-Q · filed 2022-11-14 | $2.11M derived: sum of 2 quarters · filed 2022-11-14 | |||
| 2021-03-31 | $1.04M 10-Q · filed 2022-11-14 | ||||
| 2020-12-31 | $3.82M 10-K · filed 2022-03-23 | ||||
| 2020-09-30 | $847.00K 10-Q · filed 2021-11-10 | $2.20M derived: sum of 2 quarters · filed 2021-11-10 | $2.98M derived: sum of 3 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $1.35M 10-Q · filed 2021-11-10 | $2.14M derived: sum of 2 quarters · filed 2021-11-10 | |||
| 2020-03-31 | $787.00K 10-Q · filed 2021-11-10 | ||||
| 2019-12-31 | $2.25M 10-K · filed 2021-03-24 | ||||
| 2019-09-30 | $633.00K 10-Q · filed 2020-11-10 | $1.21M derived: sum of 2 quarters · filed 2020-11-10 | $1.66M derived: sum of 3 quarters · filed 2020-11-10 | ||
| 2019-06-30 | $581.00K 10-Q · filed 2020-11-10 | $1.03M derived: sum of 2 quarters · filed 2020-11-10 | |||
| 2019-03-31 | $446.00K 10-Q · filed 2020-11-10 | ||||
| 2018-12-31 | $442.00K 10-K · filed 2020-03-26 | $441.91K 10-K · filed 2019-03-27 | |||
| 2018-09-30 | $131.00K 10-Q · filed 2019-11-12 | $132.00K derived: sum of 2 quarters · filed 2019-11-12 | |||
| 2018-06-30 | $1.00K 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |